Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4

Paul T. Golumbek, Audrey J. Lazenby, Hyam I. Levitsky, Liz M. Jaffee, Hajime Karasuyama, Mitzi Baker, Drew M. Pardoll

Research output: Contribution to journalArticlepeer-review

747 Scopus citations


The generation of antigen-specific antitumor immunity is the ultimate goal in cancer immunotherapy. When cells from a spontaneously arising murine renal cell tumor were engineered to secrete large doses of interleukin-4 (IL-4) locally, they were rejected in a predominantly T cell-independent manner. However, animals that rejected the IL-4-transfected tumors developed T cell-dependent systemic immunity to the parental tumor. This systemic immunity was tumor-specific and primarily mediated by CD8+ T cells. Established parental tumors could be cured by the systemic immune response generated by injection of the genetically engineered tumors. These results provide a rationale for the use of lymphokine gene-transfected tumor cells as a modality for cancer therapy.

Original languageEnglish (US)
Pages (from-to)713-716
Number of pages4
Issue number5032
StatePublished - Nov 1 1991
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4'. Together they form a unique fingerprint.

Cite this